Table 11 Selected registry and phase 1/2 trials in NRG1 rearranged NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Objective response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|
Schram et al | NCT02912949 | Zenocotuzumab | 35 | NR | NR |
Drilon et al | NA | Afatinib | 25 | 2.8 | NR |